search
Back to results

PROlonged Ex-vivo Normothermic Machine PERfusion for Kidney Regeneration (PROPER)

Primary Purpose

End Stage Renal Disease

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Prolonged normothermic machine perfusion
Sponsored by
Leiden University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for End Stage Renal Disease focused on measuring normothermic machine perfusion, renal transplantation, kidney transplantation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients undergoing 1st or 2nd kidney transplant
  • Patients undergoing a kidney transplantation from DCD Maastricht III & V
  • Transplant recipients aged ≥ 18 years
  • Written informed consent

Exclusion Criteria:

  • Patients undergoing 3rd or subsequent kidney transplant
  • Patients undergoing a kidney transplantation from DCD Maastricht I, II & IV
  • Transplant recipients aged < 18 years
  • Patients receiving multi-organ transplants
  • ABO/HLA incompatible transplants
  • Highly sensitized patients with a panel-reactive antibody (PRA) ≥85%
  • Kidneys with CIT > 12 hrs at the point of arrival at transplant centre
  • Kidneys with complex vascular anatomy (≥3 arteries, artery which cannot be can-nulated or attached to the patch holder)
  • Kidneys explanted from a donor on normothermic regional perfusion

Sites / Locations

  • University Medical Center GroningenRecruiting
  • Leiden University Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Prolonged normothermic machina perfusion

Arm Description

Eligible and consenting patients who will receive a donor kidney will be included for participation in this study. Current practice is to preserve donor kidneys on hypothermic machine perfusion (HMP). In this study, donor kidneys (n=18) will be taken off the HMP after arrival in the transplant center. These will then be perfused with oxygenated perfusate using the NMP device following an optimised NMP protocol.

Outcomes

Primary Outcome Measures

glomerular filtration rate (GFR)
renal function defined by the estimated glomerular filtration rate (eGFR) calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation

Secondary Outcome Measures

glomerular filtration rate (GFR)
renal function defined by the estimated glomerular filtration rate (eGFR) calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
glomerular filtration rate (GFR)
renal function defined by the estimated glomerular filtration rate (eGFR) calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
primary non-function
defined as permanent lack of graft function from the time of transplantation, was diagnosed when a kidney graft was well perfused (confirmed by ultrasound examination) but never functioned, necessitating dialysis after kidney transplantation
delayed graft function (DGF)
defined as the need for postoperative dialysis during the first 7 days after transplantation
patient and graft survival
time from transplant to patient death, and graft failure
adverse events
defined as any undesirable experience occurring to a subject during the study, whether or not considered related to the normothermic machine perfusion of the donor kidney prior to transplantation
postoperative complications
graded according to the comprehensive complication index

Full Information

First Posted
June 24, 2020
Last Updated
December 13, 2021
Sponsor
Leiden University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04693325
Brief Title
PROlonged Ex-vivo Normothermic Machine PERfusion for Kidney Regeneration
Acronym
PROPER
Official Title
PROlonged Ex-vivo Normothermic Machine PERfusion for Kidney Regeneration
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2021 (Actual)
Primary Completion Date
July 2022 (Anticipated)
Study Completion Date
January 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Leiden University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators would like to introduce and clinically evaluate prolonged normothermic machine perfusion (PNMP) to preserve and assess high-risk donor kidneys prior to transplantation.
Detailed Description
Currently kidney transplantation is the only viable option for patients with kidney failure to regain quality of life and health. The number of organs available for transplantation is insufficient with a widening gap between supply and demand. Nowadays, centers accept older and higher risk donor organs with co-morbidity, often leading to non-function, complications and with half of the patients back on dialysis within 15 years. Furthermore, many donor kidneys have to be discarded as too damaged and beyond repair. Increasing the quality and therefore transplantability of these high-risk donor organs could significantly increase the donor kidney pool. Using prolonged normothermic perfusion of marginal donor organs, the investigators aim to kick start regeneration in the kidney before transplantation, improving function and survival long-term. Furthermore, the choice to accept or decline a donor kidney organ is currently based on subjective criteria and causes great uncertainty amongst clinicians. There is a dire need for tools to aid in decision making and reduce this uncertainty. Biomarkers predictive of graft regeneration are lacking. Samples from perfused kidneys and donor recipients will be collected and analysed to allow the formulation of a kidney fitness index.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease
Keywords
normothermic machine perfusion, renal transplantation, kidney transplantation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
18 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Prolonged normothermic machina perfusion
Arm Type
Experimental
Arm Description
Eligible and consenting patients who will receive a donor kidney will be included for participation in this study. Current practice is to preserve donor kidneys on hypothermic machine perfusion (HMP). In this study, donor kidneys (n=18) will be taken off the HMP after arrival in the transplant center. These will then be perfused with oxygenated perfusate using the NMP device following an optimised NMP protocol.
Intervention Type
Procedure
Intervention Name(s)
Prolonged normothermic machine perfusion
Intervention Description
First, a cohort of DCD kidneys (n=6) will be subjected to 1 hour of NMP and subsequently transplanted [NMP1]. Before extending the duration, secondary endpoints will be evaluated. Thereafter, the duration of NMP will be prolonged to 3 hours (n=6) [PNMP3] and consequently 6 hours (n=6) [PNMP6].
Primary Outcome Measure Information:
Title
glomerular filtration rate (GFR)
Description
renal function defined by the estimated glomerular filtration rate (eGFR) calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
Time Frame
6 months post transplantation
Secondary Outcome Measure Information:
Title
glomerular filtration rate (GFR)
Description
renal function defined by the estimated glomerular filtration rate (eGFR) calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
Time Frame
1 month post transplantation
Title
glomerular filtration rate (GFR)
Description
renal function defined by the estimated glomerular filtration rate (eGFR) calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
Time Frame
3 months post transplantation
Title
primary non-function
Description
defined as permanent lack of graft function from the time of transplantation, was diagnosed when a kidney graft was well perfused (confirmed by ultrasound examination) but never functioned, necessitating dialysis after kidney transplantation
Time Frame
6 months post transplantation
Title
delayed graft function (DGF)
Description
defined as the need for postoperative dialysis during the first 7 days after transplantation
Time Frame
6 months post transplantation
Title
patient and graft survival
Description
time from transplant to patient death, and graft failure
Time Frame
6 months post transplantation
Title
adverse events
Description
defined as any undesirable experience occurring to a subject during the study, whether or not considered related to the normothermic machine perfusion of the donor kidney prior to transplantation
Time Frame
6 months post transplantation
Title
postoperative complications
Description
graded according to the comprehensive complication index
Time Frame
6 months post transplantation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing 1st or 2nd kidney transplant Patients undergoing a kidney transplantation from DCD Maastricht III & V Transplant recipients aged ≥ 18 years Written informed consent Exclusion Criteria: Patients undergoing 3rd or subsequent kidney transplant Patients undergoing a kidney transplantation from DCD Maastricht I, II & IV Transplant recipients aged < 18 years Patients receiving multi-organ transplants ABO/HLA incompatible transplants Highly sensitized patients with a panel-reactive antibody (PRA) ≥85% Kidneys with CIT > 12 hrs at the point of arrival at transplant centre Kidneys with complex vascular anatomy (≥3 arteries, artery which cannot be can-nulated or attached to the patch holder) Kidneys explanted from a donor on normothermic regional perfusion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Asel Arykbaeva
Phone
+31657216416
Email
a.s.arykbaeva@lumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Dorottya K De Vries, MD PhD
Email
d.k.de_vries@lumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ian PJ Alwayn, MD PhD
Organizational Affiliation
Leiden University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Medical Center Groningen
City
Groningen
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert A Pol, MD PhD
Email
r.pol@umcg.nl
First Name & Middle Initial & Last Name & Degree
Robert A Pol, MD PhD
Facility Name
Leiden University Medical Center
City
Leiden
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Asel Arykbaeva
Email
a.s.arykbaeva@lumc.nl

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

PROlonged Ex-vivo Normothermic Machine PERfusion for Kidney Regeneration

We'll reach out to this number within 24 hrs